. 2019 Dec 19;7(1):112–120. doi: 10.1002/acn3.50968

Table 2.

Orthostatic vital signs and Questionnaire scores at baseline and 1 month.

	Total	Atomoxetine	Midodrine	P valuea
No. of patients with nOH
Baseline	50	25	25
1 month	11/42 (26.2)	6/19 (31.6)	5/23 (21.7)	0.470
Orthostatic SBP drop (mmHg)
Baseline	26.3 ± 11.1	25.8 ± 11.7	26.7 ± 10.9	0.761
1 month	14.4 ± 14.9^†	12.3 ± 12.5^†	16.2 ± 16.7^†	0.404
Orthostatic DBP drop (mmHg)
Baseline	13.5 ± 8.5	15.1 ± 9.8	12.1 ± 7.3	0.418
1 month	3.2 ± 9.1^†	4.4 ± 9.4^†	2.2 ± 8.9^†	0.418
Orthostatic HR increase
Baseline	11.8 ± 9.7	11.1 ± 12.8	12.4 ± 6.5	0.849
1 month	7.6 ± 7.0^†	7.5 ± 8.8*	7.4 ± 5.3^†	0.425
Supine SBP (mmHg)
Baseline	128.7 ± 18.1	126.4 ± 17.7	130.5 ± 18.7	0.940
1 month	130.4 ± 18.8	128.1 ± 17.4	132.4 ± 20.1	0.830
Supine DBP (mmHg)
Baseline	80.3 ± 11.2	80.5 ± 12.4	80.0 ± 10.5	0.790
1 month	80.1 ± 11.5	80.5 ± 12.2	79.8 ± 11.2	0.830
Supine HR
Baseline	68.4 ± 13.1	72.2 ± 16.8	65.3 ± 8.2	0.235
1 month	77.4 ± 13.4^†	80.5 ± 15.2	74.9 ± 11.4^†	0.202
OHQ total
Baseline	40.8 ± 22.6	44.7 ± 23.9	37.5 ± 33.4	0.314
1 month	34.1 ± 21.7^†	35.0 ± 20.1^†	33.4 ± 23.4	0.813
OHDAS
Baseline	16.7 ± 10.9	18.2 ± 11.2	15.4 ± 10.7	0.324
1 month	14.1 ± 9.8	14.0 ± 8.3*	14.3 ± 11.1	0.751
OHSA
Baseline	24.1 ± 14.0	26.5 ± 15.7	22.1 ± 12.4	0.390
1 month	20.0 ± 13.3*	21.0 ± 13.6*	19.1 ± 13.2	0.640
BDI
Baseline	20.3 ± 12.6	21.3 ± 15.1	19.4 ± 10.3	0.733
1 month	16.4 ± 11.4^†	17.1 ± 12.7*	15.9 ± 10.5^†	0.695

Data are presented as the mean ± SD or number (percentage). nOH, neurogenic orthostatic hypotension; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; OHQ, OH questionnaire; OHDAS, orthostatic hypotension daily activity scale; OHSA, orthostatic hypotension symptom assessment, BDI, Beck depression inventory.

P value from Mann–Whitney U test or chi‐square test.

*P < 0.05, ^† P < 0.01 compared with the baseline, Wilcoxon signed‐rank test.